This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Reasons to Add Fresenius Medical Stock to Your Portfolio Now
by Zacks Equity Research
FMS continues to gain traction on the back of acquisitions & partnerships. A tough regulatory environment raises concerns.
Brookdale's Occupancy Registers a Rise to 80.5% in June 2025
by Zacks Equity Research
BKD's June occupancy improves 230 bps year over year to 80.5%, driven by stronger move-ins and move-out activity across its senior living communities.
Here's Why You Should Add PacBio Stock to Your Portfolio Now
by Zacks Equity Research
PACB benefits from strong first-quarter results, product innovation, and cost cuts to offset macroeconomic concerns and drive 2025 growth.
Should Invesco S&P MidCap 400 Pure Growth ETF (RFG) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for RFG
New Strong Buy Stocks for July 8th
by Zacks Equity Research
BMBL, HBM, HIMS, BWMX and ERO have been added to the Zacks Rank #1 (Strong Buy) List on July 8, 2025.
Health Meets Lifestyle: How Hims & Hers Is Reshaping Everyday Wellness
by Zacks Equity Research
HIMS is transforming digital wellness with personalized care, over 30 million telehealth consultations, and a Gen Z-aligned platform.
Stereotaxis Reports Positive Initial Data From MAGiC Catheter Trial
by Zacks Equity Research
STXS posts first peer-reviewed results for its MAGiC catheter, showing 94% efficacy and strong safety in arrhythmia treatment.
Hims & Hers Health, Inc. (HIMS) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Intuitive Surgical's Fifth Generation da Vinci System Receives CE Mark
by Zacks Equity Research
ISRG secures CE mark for its da Vinci 5 system, unlocking European access to its most advanced surgical platform yet.
Hims & Hers Enhances Healthcare Through AI-Driven Personalization
by Zacks Equity Research
HIMS taps AI and $870 million in funding to deliver smarter, more personalized healthcare through tech-driven innovation.
IART Stock May Rise on First Enrollment in AERA Pediatric Registry
by Zacks Equity Research
Integra enrolls first pediatric patient in AERA registry to evaluate real-world use of its ETBD system and expand ENT market presence.
Here's Why You Should Add HealthEquity Stock to Your Portfolio Now
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
Abbott Sees Upside on Diagnostics Growth, FreeStyle Libre Expansion
by Zacks Equity Research
ABT stock surges 21.7% year to date on CGM sales growth and robust diagnostics demand, even as FX and macro risks weigh on forecasts.
Is it Apt to Retain Alcon Stock in Your Portfolio for Now?
by Zacks Equity Research
ALC stays on investors' radar due to its Vision Care arm's performance and contributions from new products despite macro risks and stiff competition.
Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Hims & Hers Health, Inc. (HIMS) reached $47.96 at the closing of the latest trading day, reflecting a -3.79% change compared to its last close.
Phibro Animal Health Stock Up 52.8% in a Year: What's Driving the Rise?
by Zacks Equity Research
PAHC stock is under investors' radar due to its booming animal health sales, new product lines and rising vaccine demand.
Hims & Hers vs. LifeMD: Which Telehealth Stock Has More Upside?
by Debanjana Dey
HIMS and LFMD are surging in the telehealth race, but which one has stronger earnings growth and expansion momentum? Let's see.
BRKR Stock Gains Following the Multi-System Advanced Packaging Order
by Zacks Equity Research
Bruker ships and installs its 15th InSight WLI system as part of a 27-optical metrology unit order tied to AI chip packaging demand.
Bio-Techne's New USP Deal on mAb and Gene Therapy May Boost Its Stock
by Zacks Equity Research
TECH teams up with USP to boost mAb and gene therapy testing, aiming to simplify analytics and enhance product quality.
SYK Boosts Foot & Ankle Portfolio With FDA-Cleared Total Ankle System
by Zacks Equity Research
Stryker expands its Foot & Ankle portfolio with FDA-cleared InCompass, targeting streamlined total ankle replacement.
Reasons to Add Align Technology Stock to Your Portfolio Now
by Zacks Equity Research
ALGN's Invisalign growth, iTero innovation and solid finances fuel optimism despite forex headwinds.
Health & Fitness Stocks to Buy as the Wellness Trend Grows
by Nilanjan Choudhury
SFM, BODI, and HIMS are capitalizing on the booming wellness market with digital tools, nutrition, and holistic health solutions.
Hims & Hers Health (HIMS) Loses 22.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Hims & Hers Health (HIMS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Illumina Stock May Benefit From New Agreement to Acquire SomaLogic
by Zacks Equity Research
ILMN jumps 2.9% after striking a $350M deal to acquire SomaLogic and boost its fast-growing multiomics strategy.
GEHC Stock Gains Post FDA's Nod for Vizamyl's Expanded Indications
by Zacks Equity Research
GE HealthCare gains FDA nod to expand Vizamyl's use, unlocking new diagnostic and therapy-monitoring capabilities.